Global Diabetes Associated Ophthalmic Treatment Market

Diabetes Associated Ophthalmic Treatment Comprehensive Study by Type (Drugs, Devices), Application (Children, Adults), Disease Type (Diabetic Retinopathy, Diabetic Macular Edema, Cataracts, Glaucoma), End-user (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028

Diabetes Associated Ophthalmic Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Diabetes Associated Ophthalmic Treatment
Diabetes associated ophthalmic treatment is used to treat various types of diabetic eye diseases. Change in lifestyle and less exercise has increased the population with diabetes across the globe. However, increasing diabetic retinopathy in the patient with the age of 20 to 64 increased the demand for retinopathy treatment. The companies are focusing on the development of new drugs and innovative devices that can quickly detect eye problems and for the treatment of ophthalmic diseases.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Diabetes Associated Ophthalmic Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Ocuphire Pharma, Inc. (United States), Mayo Clinic (United States), Novo Nordisk (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (United States), LKC Technologies (United States), Roche Holding AG (Switzerland) and Bayer AG (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Novartis International AG (Switzerland) and Akorn Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Diabetes Associated Ophthalmic Treatment market by Type (Drugs and Devices), Application (Children and Adults) and Region.



On the basis of geography, the market of Diabetes Associated Ophthalmic Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Diabetic Retinopathy will boost the Diabetes Associated Ophthalmic Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Diabetes Associated Ophthalmic Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements Such as AI-based Device to Detect Diabetes Related Eye Problems

Market Growth Drivers:
Increasing Number of Diabetes Population Across the Globe Due to Change in Lifestyle and Increasing Diabetic Retinopathy in the Diabetes Patients Will Drive the Market

Challenges:
High Cost of Treatment and Drugs May Create Challenges for the Market

Restraints:
Inadequate Availability of Advanced Devices in Healthcare Facilities in the Rural Area Due to Lack of Fund

Opportunities:
Large Number of Older Adults with Diabetic Problems At Worldwide

Market Leaders and their expansionary development strategies
In January 2020, Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company announced the partnership with Apexian Pharmaceuticals, Inc. to treat patients with a variety of ophthalmic disorders and Phase 2 clinical trial of APX3330. APX3330 is an orally administered, small molecule drug candidate that improves eye health in diabetics by reducing inflammation, hypoxia signaling, and abnormal angiogenesis. The acquisition of APX3330 expands Ocuphire’s late-clinical stage small molecule ophthalmic pipeline and advance APX3330 into Phase 2 clinical ophthalmology trials for DR and DME.
In October 2023, Genentech, ADA launched new 'eye pledge' to boost awareness of diabetes-related vision loss.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Diabetes Associated Ophthalmic Treatment Providers, Diabetes Associated Ophthalmic Treatment Drug & Device Manufacturers, Suppliers and Distributors of Diabetes Associated Ophthalmic Treatment Drug & Device, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations, End-Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Drugs
  • Devices
By Application
  • Children
  • Adults
By Disease Type
  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Cataracts
  • Glaucoma

By End-user
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Diabetes Population Across the Globe Due to Change in Lifestyle
      • 3.2.2. Increasing Diabetic Retinopathy in the Diabetes Patients Will Drive the Market
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Treatment and Drugs May Create Challenges for the Market
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements Such as AI-based Device to Detect Diabetes Related Eye Problems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetes Associated Ophthalmic Treatment, by Type, Application, Disease Type, End-user and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Diabetes Associated Ophthalmic Treatment (Value)
      • 5.2.1. Global Diabetes Associated Ophthalmic Treatment by: Type (Value)
        • 5.2.1.1. Drugs
        • 5.2.1.2. Devices
      • 5.2.2. Global Diabetes Associated Ophthalmic Treatment by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Diabetes Associated Ophthalmic Treatment by: Disease Type (Value)
        • 5.2.3.1. Diabetic Retinopathy
        • 5.2.3.2. Diabetic Macular Edema
        • 5.2.3.3. Cataracts
        • 5.2.3.4. Glaucoma
      • 5.2.4. Global Diabetes Associated Ophthalmic Treatment by: End-user (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Diabetes Associated Ophthalmic Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Diabetes Associated Ophthalmic Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ocuphire Pharma, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mayo Clinic (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ypsomed AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LKC Technologies (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Diabetes Associated Ophthalmic Treatment Sale, by Type, Application, Disease Type, End-user and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Diabetes Associated Ophthalmic Treatment (Value)
      • 7.2.1. Global Diabetes Associated Ophthalmic Treatment by: Type (Value)
        • 7.2.1.1. Drugs
        • 7.2.1.2. Devices
      • 7.2.2. Global Diabetes Associated Ophthalmic Treatment by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Diabetes Associated Ophthalmic Treatment by: Disease Type (Value)
        • 7.2.3.1. Diabetic Retinopathy
        • 7.2.3.2. Diabetic Macular Edema
        • 7.2.3.3. Cataracts
        • 7.2.3.4. Glaucoma
      • 7.2.4. Global Diabetes Associated Ophthalmic Treatment by: End-user (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Diabetes Associated Ophthalmic Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetes Associated Ophthalmic Treatment: by Type(USD Million)
  • Table 2. Diabetes Associated Ophthalmic Treatment Drugs , by Region USD Million (2017-2022)
  • Table 3. Diabetes Associated Ophthalmic Treatment Devices , by Region USD Million (2017-2022)
  • Table 4. Diabetes Associated Ophthalmic Treatment: by Application(USD Million)
  • Table 5. Diabetes Associated Ophthalmic Treatment Children , by Region USD Million (2017-2022)
  • Table 6. Diabetes Associated Ophthalmic Treatment Adults , by Region USD Million (2017-2022)
  • Table 7. Diabetes Associated Ophthalmic Treatment: by Disease Type(USD Million)
  • Table 8. Diabetes Associated Ophthalmic Treatment Diabetic Retinopathy , by Region USD Million (2017-2022)
  • Table 9. Diabetes Associated Ophthalmic Treatment Diabetic Macular Edema , by Region USD Million (2017-2022)
  • Table 10. Diabetes Associated Ophthalmic Treatment Cataracts , by Region USD Million (2017-2022)
  • Table 11. Diabetes Associated Ophthalmic Treatment Glaucoma , by Region USD Million (2017-2022)
  • Table 12. Diabetes Associated Ophthalmic Treatment: by End-user(USD Million)
  • Table 13. Diabetes Associated Ophthalmic Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 14. Diabetes Associated Ophthalmic Treatment Clinics , by Region USD Million (2017-2022)
  • Table 15. Diabetes Associated Ophthalmic Treatment Others , by Region USD Million (2017-2022)
  • Table 16. South America Diabetes Associated Ophthalmic Treatment, by Country USD Million (2017-2022)
  • Table 17. South America Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 18. South America Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 19. South America Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 20. South America Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 21. Brazil Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 22. Brazil Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 23. Brazil Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 24. Brazil Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 25. Argentina Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 26. Argentina Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 27. Argentina Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 28. Argentina Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 29. Rest of South America Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 30. Rest of South America Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 31. Rest of South America Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 32. Rest of South America Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 33. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 36. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 37. Asia Pacific Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 38. China Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 39. China Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 40. China Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 41. China Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 42. Japan Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 43. Japan Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 44. Japan Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 45. Japan Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 46. India Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 47. India Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 48. India Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 49. India Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 50. South Korea Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 51. South Korea Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 52. South Korea Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 53. South Korea Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 54. Australia Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 55. Australia Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 56. Australia Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 57. Australia Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 58. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 59. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 60. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 62. Europe Diabetes Associated Ophthalmic Treatment, by Country USD Million (2017-2022)
  • Table 63. Europe Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 64. Europe Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 65. Europe Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 66. Europe Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 67. Germany Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 68. Germany Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 69. Germany Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 70. Germany Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 71. France Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 72. France Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 73. France Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 74. France Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 75. Italy Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 76. Italy Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 77. Italy Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 78. Italy Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 79. United Kingdom Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 80. United Kingdom Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 81. United Kingdom Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 82. United Kingdom Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 83. Netherlands Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 84. Netherlands Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 85. Netherlands Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 86. Netherlands Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 87. Rest of Europe Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 88. Rest of Europe Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 89. Rest of Europe Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 90. Rest of Europe Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 91. MEA Diabetes Associated Ophthalmic Treatment, by Country USD Million (2017-2022)
  • Table 92. MEA Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 93. MEA Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 94. MEA Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 95. MEA Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 96. Middle East Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 97. Middle East Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 98. Middle East Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 99. Middle East Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 100. Africa Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 101. Africa Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 102. Africa Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 103. Africa Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 104. North America Diabetes Associated Ophthalmic Treatment, by Country USD Million (2017-2022)
  • Table 105. North America Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 106. North America Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 107. North America Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 108. North America Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 109. United States Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 110. United States Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 111. United States Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 112. United States Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 113. Canada Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 114. Canada Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 115. Canada Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 116. Canada Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 117. Mexico Diabetes Associated Ophthalmic Treatment, by Type USD Million (2017-2022)
  • Table 118. Mexico Diabetes Associated Ophthalmic Treatment, by Application USD Million (2017-2022)
  • Table 119. Mexico Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2017-2022)
  • Table 120. Mexico Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2017-2022)
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Diabetes Associated Ophthalmic Treatment: by Type(USD Million)
  • Table 130. Diabetes Associated Ophthalmic Treatment Drugs , by Region USD Million (2023-2028)
  • Table 131. Diabetes Associated Ophthalmic Treatment Devices , by Region USD Million (2023-2028)
  • Table 132. Diabetes Associated Ophthalmic Treatment: by Application(USD Million)
  • Table 133. Diabetes Associated Ophthalmic Treatment Children , by Region USD Million (2023-2028)
  • Table 134. Diabetes Associated Ophthalmic Treatment Adults , by Region USD Million (2023-2028)
  • Table 135. Diabetes Associated Ophthalmic Treatment: by Disease Type(USD Million)
  • Table 136. Diabetes Associated Ophthalmic Treatment Diabetic Retinopathy , by Region USD Million (2023-2028)
  • Table 137. Diabetes Associated Ophthalmic Treatment Diabetic Macular Edema , by Region USD Million (2023-2028)
  • Table 138. Diabetes Associated Ophthalmic Treatment Cataracts , by Region USD Million (2023-2028)
  • Table 139. Diabetes Associated Ophthalmic Treatment Glaucoma , by Region USD Million (2023-2028)
  • Table 140. Diabetes Associated Ophthalmic Treatment: by End-user(USD Million)
  • Table 141. Diabetes Associated Ophthalmic Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 142. Diabetes Associated Ophthalmic Treatment Clinics , by Region USD Million (2023-2028)
  • Table 143. Diabetes Associated Ophthalmic Treatment Others , by Region USD Million (2023-2028)
  • Table 144. South America Diabetes Associated Ophthalmic Treatment, by Country USD Million (2023-2028)
  • Table 145. South America Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 146. South America Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 147. South America Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 148. South America Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 149. Brazil Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 150. Brazil Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 151. Brazil Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 152. Brazil Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 153. Argentina Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 154. Argentina Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 155. Argentina Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 156. Argentina Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 157. Rest of South America Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 158. Rest of South America Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 159. Rest of South America Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 160. Rest of South America Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 161. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Country USD Million (2023-2028)
  • Table 162. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 163. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 164. Asia Pacific Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 165. Asia Pacific Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 166. China Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 167. China Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 168. China Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 169. China Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 170. Japan Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 171. Japan Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 172. Japan Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 173. Japan Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 174. India Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 175. India Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 176. India Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 177. India Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 178. South Korea Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 179. South Korea Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 180. South Korea Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 181. South Korea Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 182. Australia Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 183. Australia Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 184. Australia Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 185. Australia Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 186. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 187. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 188. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 189. Rest of Asia-Pacific Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 190. Europe Diabetes Associated Ophthalmic Treatment, by Country USD Million (2023-2028)
  • Table 191. Europe Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 192. Europe Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 193. Europe Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 194. Europe Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 195. Germany Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 196. Germany Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 197. Germany Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 198. Germany Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 199. France Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 200. France Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 201. France Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 202. France Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 203. Italy Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 204. Italy Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 205. Italy Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 206. Italy Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 207. United Kingdom Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 208. United Kingdom Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 209. United Kingdom Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 210. United Kingdom Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 211. Netherlands Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 212. Netherlands Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 213. Netherlands Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 214. Netherlands Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 215. Rest of Europe Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 216. Rest of Europe Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 217. Rest of Europe Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 218. Rest of Europe Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 219. MEA Diabetes Associated Ophthalmic Treatment, by Country USD Million (2023-2028)
  • Table 220. MEA Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 221. MEA Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 222. MEA Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 223. MEA Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 224. Middle East Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 225. Middle East Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 226. Middle East Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 227. Middle East Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 228. Africa Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 229. Africa Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 230. Africa Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 231. Africa Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 232. North America Diabetes Associated Ophthalmic Treatment, by Country USD Million (2023-2028)
  • Table 233. North America Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 234. North America Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 235. North America Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 236. North America Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 237. United States Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 238. United States Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 239. United States Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 240. United States Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 241. Canada Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 242. Canada Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 243. Canada Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 244. Canada Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 245. Mexico Diabetes Associated Ophthalmic Treatment, by Type USD Million (2023-2028)
  • Table 246. Mexico Diabetes Associated Ophthalmic Treatment, by Application USD Million (2023-2028)
  • Table 247. Mexico Diabetes Associated Ophthalmic Treatment, by Disease Type USD Million (2023-2028)
  • Table 248. Mexico Diabetes Associated Ophthalmic Treatment, by End-user USD Million (2023-2028)
  • Table 249. Research Programs/Design for This Report
  • Table 250. Key Data Information from Secondary Sources
  • Table 251. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetes Associated Ophthalmic Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Diabetes Associated Ophthalmic Treatment: by Application USD Million (2017-2022)
  • Figure 6. Global Diabetes Associated Ophthalmic Treatment: by Disease Type USD Million (2017-2022)
  • Figure 7. Global Diabetes Associated Ophthalmic Treatment: by End-user USD Million (2017-2022)
  • Figure 8. South America Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 9. Asia Pacific Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 10. Europe Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 11. MEA Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 12. North America Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 13. Global Diabetes Associated Ophthalmic Treatment share by Players 2022 (%)
  • Figure 14. Global Diabetes Associated Ophthalmic Treatment share by Players (Top 3) 2022(%)
  • Figure 15. Global Diabetes Associated Ophthalmic Treatment share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Ocuphire Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Ocuphire Pharma, Inc. (United States) Revenue: by Geography 2022
  • Figure 19. Mayo Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 20. Mayo Clinic (United States) Revenue: by Geography 2022
  • Figure 21. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 22. Novo Nordisk (Denmark) Revenue: by Geography 2022
  • Figure 23. Ypsomed AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Ypsomed AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 27. LKC Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 28. LKC Technologies (United States) Revenue: by Geography 2022
  • Figure 29. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 33. Global Diabetes Associated Ophthalmic Treatment: by Type USD Million (2023-2028)
  • Figure 34. Global Diabetes Associated Ophthalmic Treatment: by Application USD Million (2023-2028)
  • Figure 35. Global Diabetes Associated Ophthalmic Treatment: by Disease Type USD Million (2023-2028)
  • Figure 36. Global Diabetes Associated Ophthalmic Treatment: by End-user USD Million (2023-2028)
  • Figure 37. South America Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 38. Asia Pacific Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 39. Europe Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 40. MEA Diabetes Associated Ophthalmic Treatment Share (%), by Country
  • Figure 41. North America Diabetes Associated Ophthalmic Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ocuphire Pharma, Inc. (United States)
  • Mayo Clinic (United States)
  • Novo Nordisk (Denmark)
  • Ypsomed AG (Switzerland)
  • Abbott Laboratories (United States)
  • LKC Technologies (United States)
  • Roche Holding AG (Switzerland)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
Novartis International AG (Switzerland) , Akorn Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 205 Pages 97 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetes Associated Ophthalmic Treatment Market Quantitative research analysis
Global Diabetes Associated Ophthalmic Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Ocuphire Pharma, Inc. (United States), Mayo Clinic (United States), Novo Nordisk (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (United States), LKC Technologies (United States), Roche Holding AG (Switzerland) and Bayer AG (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements Such as AI-based Device to Detect Diabetes Related Eye Problems" is seen as one of major influencing trends for Diabetes Associated Ophthalmic Treatment Market during projected period 2022-2028.
The Diabetes Associated Ophthalmic Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Diabetes Associated Ophthalmic Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Pelvic Ring Fixation Comprehensive Study by Type (Type A, Type B, Type C), Indication (Pubic Symphysis Disruption, Sacroiliac Dislocation, Sacrum Fracture, Others), Type Of Fracture (Internal Pelvic...
$ 3750
Down syndrome Comprehensive Study by Type (Trisomy 21 (Nondisjunction), Mosaicism, Translocation), Disorder Severity (Mild Down Syndrome (IQ: 50–69), Moderate Down Syndrome (IQ: 35–50), Severe Down S...
$ 3650
Fibrosarcoma Treatment Comprehensive Study by Type (Infantile/Congenital-Type Fibrosarcoma, Adult-Type Fibrosarcoma), Technology (X-Ray, Computed Tomography (Ct), Magnetic Resonance Imaging (Mri), Bo...
$ 3750
Brain Hemorrhage Comprehensive Study by Drug (Anti-hypertensive Drugs, Anti-convulsants Drugs, Hyperosmostic Drugs, Others (others include Anti-epileptic Drugs, Anti-pyretic Drugs, etc.)), Distributi...
$ 3750
Acromegaly Gigantism Treatment Comprehensive Study by Type (Somatostatin analogs, GHRA), End Use (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028
$ 3500
Overdenture Implant Comprehensive Study by Type (Tooth-Supported Overdentures, Implant-Supported Overdentures), Application (Hospital, Dental Clinic, Others) Players and Region - Global Market Outloo...
$ 3500